Module

Nonhormonal Adjuvant Therapy for Breast Cancer

Source: Breast Cancer Annual Update 2005

Nonhormonal Adjuvant Therapy for Breast Cancer


Program Director: Clifford A. Hudis, MD

Faculty:

  • Edith A. Perez, MD

CME CREDIT INFORMATION

Release Date: 10/31/05

Expiration Date: 10/30/06


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.1 Nursing CE credits

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate recent data on the efficacy and safety of trastuzumab in combination with cytotoxic chemotherapy as adjuvant treatment for early-stage breast cancer.

  • Describe the role of taxanes in early-stage breast cancer, particularly with regard to patient selection, dosing regimens, and scheduling.

  • Review the efficacy and safety of cyclophosphamide, methotrexate, 5-fluorouracil (CMF), and anthracycline-containing cytotoxic regimens in early-stage breast cancer.


Content includes:

  • Early Use of Adjuvant Chemotherapy for Breast Cancer
  • Taxanes: Adjuvant Trials From 1990-2000
  • Adjvuant Trastuzumab
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.